The Exchange had sought clarification from IOL Chemicals and Pharmaceuticals Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act. -2. 2013 or as per Indian Accounting Standard. The response of the Company is enclosed.
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The NSE had asked IOL Chemicals and Pharmaceuticals to clarify why its Q3 FY26 (ended 31 Dec 2025) financial results appeared not to follow the format prescribed under Schedule III of the Companies Act, 2013, and why the Standalone and Consolidated numbers looked the same. The company replied that both sets of results were prepared in full compliance with Indian Accounting Standards and the Schedule III format, with no deviation. It explained that the figures appear similar because only one Section 8 subsidiary is operational, while the other subsidiaries have not started business, so differences are limited to items like profit, depreciation, and other expenses. The company has requested the exchange to accept the Q3 results as originally filed on 11 February 2026.
This is a routine exchange query on financial reporting format and does not indicate any penalty, financial irregularity, or governance issue. No material impact is expected on shareholders or the stock price.